Mast cell tumors (MCT) are the most common skin tumors in dogs. Research shows MCTs account for about 20% of all canine skin cancers diagnosed in veterinary practices. In fact, MCTs are so common VerticalVet’s Chief Veterinary Officer Dr. Ernie Ward teaches young vets to presume any lump or bump on or just underneath the skin is a mast cell tumor until proven otherwise.
MCTs have always been a clinical challenge in veterinary medicine, but a new treatment is revolutionizing how we take aim at this common cancer.
This edition of VerticalVet’s Vet Med School features QBiotics Professional Services Director, Pamela Jones, DVM, DACVIM (Oncology), DACVR (Radiation Oncology), and Virbac’s Cristiano von Simson, DVM, MBA. They join Dr. Ward and review the indications, usage, and positive impact on veterinary patient care STELFONTA® is having in the US.
If you’re interested in learning about the latest advancement in canine cancer therapy and how it can help your patients, this webinar is for you! If you’ve tried STELFONTA® on a few cases but want to better understand the mechanisms of action behind this revolutionary drug, Dr. Jones and von Simson have you covered!
Thanks, Virbac, for sharing this information with our members!
Click here to view Stelfonta safety summary: documentcloud.adobe.com/link/...
Негізгі бет Үй жануарлары мен аңдар Changes in the Veterinary Industry: STELFONTA® (tigilanol tiglate): New Mast Cell Tumor Treatment
Пікірлер: 7